Meridian Bioscience (VIVO) Gets FDA Clearance for ImmunoCard C. difficile GDH

Meridian Bioscience, Inc., Cincinnati, Ohio (Nasdaq: VIVO) has received FDA clearance for a new Clostridium difficile assay, ImmunoCard C. difficile GDH. This test detects the C. difficile common antigen glutamate dehydrogenase (or GDH). This assay has already been successfully launched and accepted in global markets as an excellent screening option for C. difficile. The GDH common antigen is present in both toxigenic and nontoxigenic strains of C. difficile. Toxigenic strains of C. difficile are frequently associated with hospital and community-acquired diarrhea and can lead to life-threatening complications or death. Therefore, laboratories can use this highly sensitive screening test to identify patients with a suspected C. difficile infection and then reflex positives to a sensitive and more specific molecular assay like illumigene® C. difficile, which can confirm infection with the toxin-producing strains. Meridian Bioscience is the only manufacturer that can provide a complete portfolio of C. difficile testing solutions that meets the needs of its global customers. ImmunoCard C. difficile GDH, used in conjunction with illumigene C. difficile, empowers cost-sensitive laboratories with an economical algorithmic option for C. difficile diagnostic testing.

---

Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!

You May Also Be Interested In

• Auxilium (AUXL) Files Suit Against Watson (WPI) Over Testim 1% Gel
• Auxilium Pharma (AUXL), Glaxo (GSK) Enter Testim 1% Co-Promotion Agreement
• Repros Therapeutics (RPRX) Modifies Pivotal Androxal Protocol

Create E-mail Alert Related Categories

Corporate News, FDA

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?

Follow StreetInsider.com On Twitter